image credit- shutterstock
Bio-Thera Solutions, a China-based biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of India's Dr. Reddy’s Laboratories, have reached commercialisation and license agreements for BAT2206, a Proposed Stelara Biosimilar, and BAT2506, a Proposed Simponi Biosimilar.
Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506. Dr. Reddy’s will be responsible for seeking regulatory approvals as well as commercialisation in the licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, Vietnam. In addition, Dr. Reddy’s will also receive the exclusive commercial rights to BAT2206 in Colombia.
“This is our first partnership focused solely on Southeast Asia and Dr. Reddy’s is the perfect partner to help bring BAT2206 AND BAT2506 to patients in the region”, said Dr Shengfeng Li, CEO of Bio-Thera.
BAT2206 is a proposed biosimilar to Jansen’s Stelara which is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing shared p40 from binding to the IL-12Rβ1 receptor protein expressed on the surface of immune cells.
BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha). Originator product Simponi® is approved in the US for moderate to severe rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis.
